SK Biopharmaceuticals (326030:KS) PT Lowered to KRW100,000 at Citi
Tweet
Share
E-mailGet Alerts 326030:KS Hot Sheet
Price: $0.00 --0%
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 8
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 8
Join SI Premium – FREE
Citi lowered its price target on SK Biopharmaceuticals (326030:KS) to KRW100,000.00 (from KRW122,000.00) while maintaining a Buy rating.
You May Also Be Interested In
- Bank Mandiri (BMRI:IJ) (PPERF) PT Raised to IDR11,069 at Morgan Stanley
- Cholamandalam Investment and Finance (CIFC:IN) PT Raised to INR740 at HSBC
- Wall Street analysts switch stance on Meta Platforms (META) following Q4 earnings
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Intl RatingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
